Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.50 |
| ▸ | RARB | P10826 | 3/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11561346 | 1.00 | MEN1 (1.00) | MEN1KMT2ATDP1TP53TSHR | |
| SCHEMBL992112 | 1.00 | MEN1 (1.00) | MEN1KMT2ATDP1TP53TSHR | |
| SCHEMBL9060429 | 1.00 | MEN1 (1.00) | MEN1KMT2ATDP1TP53TSHR | |
| SCHEMBL11558887 | 1.00 | MEN1 (1.00) | MEN1KMT2ATDP1TP53TSHR | |
| SCHEMBL13193431 | 1.00 | MEN1 (1.00) | MEN1KMT2ATDP1TP53TSHR | |
| Tofa SCHEMBL11555343 | 0.98 | MEN1 (0.97) | MEN1KMT2ATDP1TP53TSHR | |
| SCHEMBL8784383 | 0.98 | KMT2A (0.97) | MEN1KMT2ATDP1TP53TSHR | |
| SCHEMBL10669914 | 0.92 | TDP1 (0.84) | MEN1KMT2ATDP1TP53TSHR | |
| SCHEMBL10669926 | 0.92 | TDP1 (0.84) | MEN1KMT2ATDP1TP53TSHR | |
| SCHEMBL10423243 | 0.92 | TDP1 (0.84) | MEN1KMT2ATDP1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 952 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034091-A1 | Compositions and Methods for Treating Metabolic Disorders | UNIV CALIFORNIA (US) | 2026-02-05 | — | — | US | claimed |
| US-20250297321-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | INST NAT SANTE RECH MED (FR) | 2025-09-25 | — | — | US | claimed |
| EP-4561557-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | The Regents of the University of California (US) | 2025-06-04 | — | — | EP | claimed |
| US-20250161886-A1 | ZINC IMIDAZOLE SALICYLALDOXIME-BASED ADSORPTIVE MEMBRANES FOR REMOVAL OF METAL IONS FROM AQUEOUS SOLUTIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2025-05-22 | — | — | US | claimed |
| CN-119969979-A | Monitoring method and system for care of home elderly cerebral apoplexy patients | 徐州医科大学 | 2025-05-13 | — | — | CN | claimed |
| CN-119855586-A | Compositions and methods for treating metabolic disorders | 加利福尼亚大学董事会 | 2025-04-18 | — | — | CN | claimed |
| CN-119548487-A | Application of 5- (tetradecyloxy) -2-furoic acid in preparation of medicines for inhibiting osteoclast differentiation and function | 浙江工业大学 | 2025-03-04 | — | — | CN | claimed |
| WO-2025029574-A2 | ZINC IMIDAZOLE SALICYLALDOXIME-BASED ADSORPTIVE MEMBRANES FOR REMOVAL OF METAL IONS FROM AQUEOUS SOLUTIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2025-02-06 | — | — | WO | claimed |
| EP-2836534-B1 | HIGH FUNCTIONAL POLYESTER POLYOLS | HUNTSMAN INT LLC (US) | 2024-12-25 | — | — | EP | claimed |
| EP-4469602-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | Université Paris Cité (FR) | 2024-12-04 | — | — | EP | claimed |
| EP-0738107-A1 | INHIBITORS OF FATTY ACID SYNTHESIS AS ANTIMICROBIAL AGENTS | THE JOHNS HOPKINS UNIVERSITY (US) | 1996-10-23 | — | — | EP | claimed |
| WO-1996013519-A1 | ACTIVATION OF A HUMAN STEROID RECEPTOR | MERCK & CO., INC. (US) | 1996-05-09 | — | — | WO | claimed |
| WO-1996013257-A1 | USE OF RECEPTOR POTENTIATORS | MERCK & CO., INC. (US) | 1996-05-09 | — | — | WO | claimed |
| WO-1995019706-A1 | INHIBITORS OF FATTY ACID SYNTHESIS AS ANTIMICROBIAL AGENTS | THE JOHNS HOPKINS UNIVERSITY (US) | 1995-07-27 | — | — | WO | claimed |
| WO-1995019765-A1 | CERTAIN CERULENIN-GERANYL AND DODECANOIC ACID DERIVATIVES | CHEKTEC CORPORATION (US) | 1995-07-27 | — | — | WO | claimed |
| EP-0651636-A1 | CHEMOTHERAPY FOR CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 1995-05-10 | — | — | EP | claimed |
| WO-1994021230-A1 | METHOD AND COMPOSITIONS FOR DISRUPTING THE EPITHELIAL BARRIER FUNCTION | CELLEGY PHARMACEUTICALS, INC. (US) | 1994-09-29 | — | — | WO | claimed |
| WO-1994002108-A1 | CHEMOTHERAPY FOR CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 1994-02-03 | — | — | WO | claimed |
| US-4146623-A | SUBSTITUTED FUROIC ACIDS AND ESTERS | RICHARDSON-MERRELL INC. (US) | 1979-03-27 | — | — | US | claimed |
| US-4110351-A | Hypolipidemic agents RO- or RS- substituted furoic acids, esters and salts | RICHARDSON-MERRELL INC. (US) | 1978-08-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034091-A1 | Compositions and Methods for Treating Metabolic Disorders | LIPC, GPR119, PNLIP | MEN1 3713/4885KMT2A 3144/4885TDP1 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.